Qiagen (NASDAQ:QGEN) was downgraded by TheStreet from a “b-” rating to a “c+” rating in a report issued on Thursday.

A number of other equities research analysts have also weighed in on the stock. Deutsche Bank restated a “buy” rating on shares of Qiagen in a report on Friday, December 1st. Commerzbank restated a “buy” rating on shares of Qiagen in a report on Tuesday, December 12th. Goldman Sachs Group started coverage on shares of Qiagen in a report on Monday, January 29th. They issued a “buy” rating and a $39.00 price objective on the stock. Cowen restated a “hold” rating and issued a $34.00 price objective on shares of Qiagen in a report on Thursday, December 21st. Finally, BidaskClub upgraded shares of Qiagen from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. Nine analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $35.33.

Qiagen (NASDAQ QGEN) opened at $31.81 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.33 and a quick ratio of 4.78. Qiagen has a 1 year low of $27.74 and a 1 year high of $36.34. The company has a market cap of $7,340.00, a P/E ratio of 81.56, a price-to-earnings-growth ratio of 1.98 and a beta of 1.03.

Qiagen announced that its Board of Directors has authorized a share buyback plan on Wednesday, January 31st that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Institutional investors and hedge funds have recently made changes to their positions in the company. American International Group Inc. acquired a new stake in shares of Qiagen in the 4th quarter valued at $154,000. Lourd Capital LLC acquired a new stake in Qiagen during the 4th quarter worth $223,000. Koch Industries Inc. acquired a new stake in Qiagen during the 2nd quarter worth $231,000. Hartford Investment Management Co. acquired a new stake in Qiagen during the 3rd quarter worth $231,000. Finally, Trexquant Investment LP acquired a new stake in Qiagen during the 3rd quarter worth $234,000. Institutional investors and hedge funds own 62.49% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/02/10/qiagen-qgen-lowered-to-c-at-thestreet.html.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.